Latest news with #Bristol-MyersSquibb
CNBC
16-07-2025
- Business
- CNBC
Cramer's Lightning Round: 'You can speculate with' CleanSpark
New Gold: "It's ok. I mean, why not buy Agnico Eagle? That's the one I really, really like. They're doing so well." D-Wave Quantum: "I want you to own this D-Wave." Bristol-Myers Squibb: "Never seen it this cheap. We're holding it. I did have high hopes central nervous system drug. It better work. If it doesn't work, we're going to get rid of it." CleanSpark: "You can speculate with it. As long as you understand that it's speculation and nothing more." Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest The CNBC Investing Club Charitable Trust owns shares of Bristol-Myers Squibb.
Business Insider
09-07-2025
- Business
- Business Insider
Analysts Conflicted on These Healthcare Names: Centene (CNC) and Bristol-Myers Squibb (BMY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Centene (CNC – Research Report) and Bristol-Myers Squibb (BMY – Research Report). Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Centene (CNC) Bernstein analyst Lance Wilkes maintained a Buy rating on Centene yesterday and set a price target of $86.00. The company's shares closed last Tuesday at $32.60. According to Wilkes is a 1-star analyst with an average return of -2.7% and a 43.4% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and HCA Healthcare. Currently, the analyst consensus on Centene is a Moderate Buy with an average price target of $63.08, which is a 91.5% upside from current levels. In a report issued on July 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $65.00 price target. Bristol-Myers Squibb (BMY) In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb. The company's shares closed last Tuesday at $47.04. According to Breen is a 2-star analyst with an average return of 3.3% and a 61.9% success rate. Breen covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and Eli Lilly & Co. The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $59.53 average price target, representing a 27.6% upside. In a report issued on June 27, BMO Capital also maintained a Hold rating on the stock with a $53.00 price target.
Time of India
28-06-2025
- Health
- Time of India
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
Bengaluru: The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a safety program to protect patients from risky drugs, for currently approved CAR-T cell immunotherapies. REMS is required by the FDA to ensure a drug's benefits outweigh its risks by managing serious safety concerns. The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed warnings for cytokine release syndrome and neurological toxicities, and medication guides. The cancer therapies include Bristol-Myers Squibb's Breyanzi and its partnered therapy Abecma with 2seventy bio , Johnson & Johnson's unit Janssen and Legend Biotech's Carvykti, Novartis AG's Kymriah, and Gilead Sciences' unit Kite's Tecartus and Yescarta. Bristol-Myers Squibb and Gilead Sciences did not immediately respond to Reuters' requests for comment. These are gene therapies that are currently approved to treat blood cancers, such as multiple myeloma and certain types of leukemia and lymphoma, the health regulator said. CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body. In January 2024, the FDA asked several drugmakers to add a serious warning on the label of their cancer therapies that use CAR-T technology after reports of T-cell malignancies and adverse events identified since approval. The FDA earlier said the risk of T-cell malignancies including leukemia and lymphoma applies to all therapies in the class and can lead to hospitalization and death.
Yahoo
17-06-2025
- Business
- Yahoo
Wall Street Can't Ignore This: China's Biotech Stocks Are Exploding--One Is Up 283%
China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech's AI-fueled rallythanks to a wave of billion-dollar licensing deals and red-hot IPOs. Pfizer said last month it will pay up to $1.25 billion to license an experimental cancer drug from 3SBio (TRSBF) and invest another $100 million in the firm's stock. Just weeks later, Bristol-Myers Squibb inked a deal worth up to $11.5 billion for a cancer therapy originally licensed by Germany's BioNTech from China's Biotheus. Those two deals alone have ignited a frenzy. 3SBio shares have soared 283% year-to-date. RemeGen, another licensing contender, is up 270% as of June. Investors aren't just chasing dealsthey're also buying into the IPO pipeline. Duality Biotherapeutics, which focuses on cancer immunotherapies, more than doubled on its first day of trading in April and has since gained 189%. Jiangsu Hengrui, China's biggest drugmaker by market value, surged 25% on debut in May. Even more striking? The pace of dealmaking. M&A involving Chinese biotech firms hit $36.9 billion in Q1more than half of global totals. Chinese biotech is having its own DeepSeek moment, said Dong Chen, chief Asia strategist at Pictet Wealth Management, referencing the AI boom that fueled Chinese tech earlier this year. Still, not everyone's chasing the highs. Some healthcare-focused funds are rotating out, preferring stable compounders with steady dividends. Others see the recent mega-deals as one-offs, and aren't ready to assign premium multiples just yet. But even with macro headwinds, analysts like those at Jefferies remain optimistic. Many Chinese biotech firms already operate as partners to U.S. drugmakers, not exportersmeaning tariffs may have limited impact. And with top scientific talent returning home amid geopolitical tensions, R&D momentum could accelerate. In short: China's biotech surge might still be in the early innings. This article first appeared on GuruFocus.
Yahoo
17-06-2025
- Business
- Yahoo
Wall Street Can't Ignore This: China's Biotech Stocks Are Exploding--One Is Up 283%
China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech's AI-fueled rallythanks to a wave of billion-dollar licensing deals and red-hot IPOs. Pfizer said last month it will pay up to $1.25 billion to license an experimental cancer drug from 3SBio (TRSBF) and invest another $100 million in the firm's stock. Just weeks later, Bristol-Myers Squibb inked a deal worth up to $11.5 billion for a cancer therapy originally licensed by Germany's BioNTech from China's Biotheus. Those two deals alone have ignited a frenzy. 3SBio shares have soared 283% year-to-date. RemeGen, another licensing contender, is up 270% as of June. Investors aren't just chasing dealsthey're also buying into the IPO pipeline. Duality Biotherapeutics, which focuses on cancer immunotherapies, more than doubled on its first day of trading in April and has since gained 189%. Jiangsu Hengrui, China's biggest drugmaker by market value, surged 25% on debut in May. Even more striking? The pace of dealmaking. M&A involving Chinese biotech firms hit $36.9 billion in Q1more than half of global totals. Chinese biotech is having its own DeepSeek moment, said Dong Chen, chief Asia strategist at Pictet Wealth Management, referencing the AI boom that fueled Chinese tech earlier this year. Still, not everyone's chasing the highs. Some healthcare-focused funds are rotating out, preferring stable compounders with steady dividends. Others see the recent mega-deals as one-offs, and aren't ready to assign premium multiples just yet. But even with macro headwinds, analysts like those at Jefferies remain optimistic. Many Chinese biotech firms already operate as partners to U.S. drugmakers, not exportersmeaning tariffs may have limited impact. And with top scientific talent returning home amid geopolitical tensions, R&D momentum could accelerate. In short: China's biotech surge might still be in the early innings. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
